Cervos Medical's CERVOS® KeyPRP System Achieves EU MDR Certification Advancing Regenerative Medicine with Quality, Safety, and Exclusive European Distribution through Aspire Medical

AVON, Mass., May 13, 2025 /PRNewswire/ -- Cervos Medical, a wholly owned subsidiary of Ranfac Corp, is proud to announce the CERVOS® KeyPRP System has received official certification under the European Union Medical Device Regulation (MDR) EU 2017/745. This certification affirms the system's compliance with the EU's most stringent standards for medical device safety, performance, and quality.
"Getting CE (MDR) certification for our Platelet Separator isn't just about meeting regulations—it's proof of our commitment to safety, quality, and compliance," said Michaela Gates, Quality Assurance Project Manager at Ranfac. "We are incredibly proud of our team's hard work here at Ranfac. With this certification, we're excited to explore new markets in the EU and see the impact of our CE-marked Platelet Separator growth."
The MDR certification represents a major milestone in Cervos Medical's ongoing mission to support healthcare providers with innovative regenerative solutions. In Europe, the CERVOS® KeyPRP System is available exclusively through Aspire Medical, Cervos's official European sales partner.
"This certification validates our ongoing dedication to product excellence and patient safety," said Eric Kreuz, Vice President of Quality Assurance and Regulatory Affairs at Ranfac. "With the strength and support of our parent company, Ranfac Corp, we are well-positioned to bring innovative regenerative technologies to clinicians and patients across global markets."
Cervos Medical continues to lead in the development of advanced autologous tissue processing systems, supporting clinicians in the areas of platelet-rich plasma (PRP), bone marrow aspiration, and adipose tissue processing.
About Cervos MedicalCervos Medical is a regenerative medicine company focused on developing innovative, minimally invasive technologies for autologous tissue collection and processing. A wholly owned subsidiary of Ranfac Corp, Cervos combines clinical insight with advanced engineering to deliver solutions that meet the highest regulatory and performance standards.
About Ranfac CorporationBased in Avon, Massachusetts, Ranfac Corp has been a trusted name in medical device manufacturing for over 100 years.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cervos-medicals-cervos-keyprp-system-achieves-eu-mdr-certification-advancing-regenerative-medicine-with-quality-safety-and-exclusive-european-distribution-through-aspire-medical-302454349.html
SOURCE Cervos Medical

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Upturn

28 minutes ago

• Business Upturn

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein. 'CHMP's positive opinion takes us a step closer to being able to market our proposed biosimilar in Europe, which is excellent news for patients and their caregivers. Alvotech looks forward to increasing access to this vital biologic treatment for eye disorders,' said Joseph McClellan, Chief Scientific Officer of Alvotech. Advertisement 'We are pleased with the CHMP's positive opinion, which marks an important milestone in our mission to bring high-quality, specialist medicines to patients across Europe,' said Nick Warwick, Chief Medical Officer of Advanz Pharma. The CHMP opinion recommends granting of a marketing authorization for AVT06 intended for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation (myopic CNV). Alvotech is responsible for the development and commercial supply of the proposed biosimilar. Advanz Pharma is responsible for registration and has exclusive commercialization rights for most countries in Europe. In 2024, global sales of Eylea® were about US$9 billion, and one third of these sales were in Europe [1]. In January 2024 Alvotech announced positive top-line results from a confirmatory clinical study with AVT06 (AVT06-GL-C01) comparing the efficacy, safety, and immunogenicity of the proposed biosimilar to Eylea® in patients with neovascular (wet) AMD. The study met its primary endpoint, with results demonstrating therapeutic equivalence between Alvotech's biosimilar candidate and Eylea® [2]. Alvotech is also developing AVT29, a proposed biosimilar to Eylea® HD, a higher dose (aflibercept 8 mg) aflibercept. Advanz has licensed the distribution rights from Alvotech for both biosimilar candidates, for the same territory. About AVT06 (aflibercept) AVT06 is a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept), which binds vascular endothelial growth factors (VEGF), inhibiting the binding and activation of VEGF receptors, neovascularization, and vascular permeability [3]. AVT06 is an investigational product and has not received regulatory approval in any country. Biosimilarity has not been established by regulatory authorities and is not claimed. Sources [1] Global Data and IQVIA [2] Agostini, H. (2025). A randomized, double-masked parallel-group, multicenter clinical study evaluating the efficacy and safety of the biosimilar candidate AVT06 compared to the reference product aflibercept in participants with neovascular age-related macular degeneration. Expert Opinion on Biological Therapy, 1–15. [3] Use of trademarks Elyea® is a registered trademark of Regeneron Pharmaceuticals Inc. and Bayer AG. About Alvotech Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech's current pipeline includes eight disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech's commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit . None of the information on the Alvotech website shall be deemed part of this press release. About Advanz Pharma Partner of choice in specialty, hospital, and rare disease medicines. Advanz Pharma is a global pharmaceutical company with the purpose to improve patients' lives by providing and enhancing the specialty, hospital, and rare disease medicines they depend on. Our headquarters are in London, UK. We have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia, a Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialization partner network. Advanz Pharma's product portfolio and pipeline comprises innovative medicines, biosimilars & specialty generics, and originator brands. Our products cover a broad range of therapeutic areas, including hepatology, rheumatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare disease medicines. Our ambition is to be a partner of choice for the commercialization of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with biopharma and development companies to bring medicines to patients. We can only achieve this due to our dedicated and highly qualified employees, acting in line with our company values of entrepreneurship, speed, and integrity. Alvotech Forward Looking Statements Certain statements in this communication may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial or operating performance of Alvotech and may include, for example, Alvotech's expectations regarding future growth, results of operations, performance, future capital and other expenditures, competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory review and interactions, the satisfactory responses to the FDA's inspection findings and resolution of other deficiencies conveyed following the re-inspection of Alvotech's manufacturing site, the potential approval, including for AVT02, AVT04, and the product candidates in scope of the partnership with Advanz, by the FDA and other regulatory agencies and commercial launch of its product candidates, the timing of the announcement of clinical study results, the commencement of patient studies, regulatory applications, approvals and market launches, and the estimated size of the total addressable market of Alvotech's pipeline products. In some cases, you can identify forward-looking statements by terminology such as 'may', 'should', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential' or 'continue', or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech's control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the ability to reach development milestones under commercial partnership agreements including the partnership with Advanz; (2) the ability to raise substantial additional funding, which may not be available on acceptable terms or at all; (3) the ability to maintain stock exchange listing; (4) changes in applicable laws or regulations; (5) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (6) Alvotech's estimates of expenses and profitability; (7) Alvotech's ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (8) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (10) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (11) the ability of Alvotech or its partners, including Advanz, to gain approval from regulators for planned clinical studies, study plans or sites; (12) the ability of Alvotech's partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (13) Alvotech's ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (14) the success of Alvotech's current and future collaborations, joint ventures, partnerships or licensing arrangements, including the partnership with Advanz; (15) Alvotech's ability, and that of its commercial partners, including Advanz, to execute their commercialization strategy for approved products; (16) Alvotech's ability to manufacture sufficient commercial supply of its approved products; (17) the outcome of ongoing and future litigation regarding Alvotech's products and product candidates; (18) the potential impact of the ongoing COVID-19 pandemic on the FDA's review timelines, including its ability to complete timely inspection of manufacturing sites; (19) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, war in Ukraine and global geopolitical tension, and the ongoing and evolving COVID-19 pandemic on the Alvotech's business, financial position, strategy and anticipated milestones; and (20) other risks and uncertainties set forth in the sections entitled 'Risk Factors' and 'Cautionary Note Regarding Forward-Looking Statements' in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication. Advanz Pharma Forward Looking Statements Certain statements in this press release are forward-looking statements. These statements may be identified by words such as 'anticipate', 'expectation', 'belief', 'estimate', 'plan', 'target', 'project', 'will', 'may', 'should' or 'forecast' and similar expressions, or by their context. Although Advanz Pharma believes that these assumptions were reasonable when made, by their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions affecting the industry, intense competition in the markets in which Advanz Pharma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Advanz Pharma's markets, and other factors beyond the control of Advanz Pharma. Neither Advanz Pharma nor any of its directors, officers, employees, advisors, or any other person is under any obligation to update or keep current the information contained in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this press release. Statements contained in this press release regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. No obligation is assumed to update any forward-looking statements. The information contained in this press release is provided as at the date of this document and is subject to change without notice. MEDIA CONTACTS Alvotech Global Communications and Investor Relations Benedikt Stefansson [email protected] Advanz Pharma Global Corporate Communications Courtney Baines [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.

Yahoo

an hour ago

• Yahoo

Europe Electric Vehicle Battery Testing, Inspection, and Certification Industry Report 2025: Market to Hit $2.21 Billion by 2034 - Expanding Second-Life Applications and Recycling of EV Batteries

The Europe EV battery testing, inspection, and certification market is expected to surge from $410.9 million in 2024 to $2.21 billion by 2034, with a robust CAGR of 18.33%. Key growth drivers include stringent EU regulations, increased EV adoption, and advances in testing technology. Comprehensive testing mitigates risks such as thermal runaway and capacity fade, ensuring battery safety and compliance. The market's expansion is bolstered by EU incentives and sustainability goals, with a focus on regulatory standards and innovative technologies like AI diagnostics and digital twins, enhancing accuracy and efficiency. Key players include DEKRA SE and TÜV SÜD. European Electric Vehicle Battery Testing, Inspection, and Certification Market Dublin, June 23, 2025 (GLOBE NEWSWIRE) -- The "Europe Electric Vehicle Battery Testing, Inspection, and Certification Market: Focus on Vehicle Type, Stage Type, Service Type, Propulsion Type, Battery Type, Testing Parameter Type, Sourcing Type, and Country-Level Analysis - Analysis and Forecast, 2024-2034" report has been added to Europe EV battery testing, inspection, and certification market is projected to reach $2.21 billion by 2034 from $410.9 million in 2024, growing at a CAGR of 18.33% during the forecast period 2024-2034. Strict national and EU battery restrictions, the growing popularity of electric vehicles, and ongoing testing technology advancements are the main drivers of Europe's industry expansion. By reducing hazards like thermal runaway, capacity fade, and performance loss, thorough testing, inspection, and certification services verify EV battery safety, dependability, and regulatory compliance. Market expansion is further accelerated by EU incentives and sustainability goals. The market for EV battery testing, inspection, and certification has grown significantly in Europe as a result of stricter EU laws and a rise in the use of electric vehicles. Under frameworks such as the EU Battery Regulation, UN 38.3, and CE marking, services include environmental stress screening, safety and abuse protocols (including thermal runaway and short-circuit tests), performance testing at the cell and pack level, lifecycle and capacity retention analysis, and type-approval laboratory authorisations and ISO 17025 accreditation guarantee uniformity and legitimacy throughout Europe's testing infrastructure. Digital twin modelling, AI-powered diagnostics, high-throughput automated rigs, and sophisticated calorimetry are examples of technological advancements that have improved throughput, accuracy, and cost-efficiency. On-site gigafactory labs and specialised contract-testing networks are expanding because to increased government incentives for local battery manufacture and circular economy Equipment Manufacturers (OEMs) and Tier 1 suppliers are reducing logistical risks and meeting strict type-approval schedules by striking a balance between partnerships and in-house facility investments. The expanding market for second-life batteries increases the need for repurposing certificates, grading procedures, and state-of-health evaluations. With Europe's strong EV rollout plans, stricter safety regulations, and strategic push for battery sovereignty, the market is expected to grow at a double-digit CAGR through the late 2020s despite obstacles like high capital requirements for sophisticated equipment, changing test standards, and a shortage of skilled can this report add value to an organization?This report provides invaluable insights into the Europe EV battery testing, inspection, and certification market, equipping organizations with the knowledge needed for strategic decision-making and market forecasting. It comprehensively analyzes emerging technologies, regulatory shifts, and competitive dynamics, helping businesses identify growth opportunities and align their offerings with evolving industry needs. Additionally, the report provides an in-depth examination of key market players, their strategies, and business models, enabling organizations to stay ahead in a competitive and compliance insights are also covered, offering a detailed assessment of international testing standards, safety regulations, and sustainability initiatives to ensure market readiness. Furthermore, regional and segmentation analyses shed light on growth patterns, challenges, and opportunities across different markets, supporting targeted market entry and expansion strategies. By leveraging the findings of this report, businesses can drive innovation, enhance operational efficiency, and secure a competitive advantage in the evolving EV battery testing and certification landscape. Europe Electric Vehicle Battery Testing, Inspection, and Certification Market Trends, Drivers and Challenges Trends Harmonization of safety and performance protocols under the EU Battery Regulation, CE-marking and UN 38.3 to streamline certification. Deployment of AI-driven diagnostics, digital-twin simulations and high-throughput automated testing rigs. Expansion of on-site testing capacity at gigafactories alongside contract-lab networks to reduce lead times. Specialized thermal-management and abuse-testing services for next-gen chemistries and fast-charging use cases. Drivers Stringent EU and national regulations mandating rigorous testing, inspection and certification for safety, performance and environmental compliance. Rapid EV adoption in Europe, prompting OEMs and Tier-1 suppliers to invest in in-house and outsourced testing to meet approval timelines. Advances in battery materials and pack designs increasing demand for electrical, mechanical, thermal and safety-abuse testing. EU strategic focus on battery sovereignty, driving local investment in testing infrastructure and accreditation bodies. Challenges High capital and operational costs for advanced testing equipment and limited availability of skilled lab personnel. Rapidly evolving regulatory landscape requiring frequent updates to test protocols and certification criteria. Fragmented national accreditation schemes and data-sovereignty rules complicating cross-border service delivery. Limited second-life and recycling infrastructure, creating gaps in inspection and certification for repurposed batteries. Key Market Players and Competition Synopsis DEKRA SE TUV SUD SGS Societe Generale de Surveillance SA Applus+ Bureau Veritas Intertek Group plc TUV Rheinland VDE Renewables GmbH TUV NORD GROUP DNV GL Element Materials Technology Key Attributes: Report Attribute Details No. of Pages 131 Forecast Period 2024 - 2034 Estimated Market Value (USD) in 2024 $410.9 Million Forecasted Market Value (USD) by 2034 $2210 Million Compound Annual Growth Rate 18.3% Regions Covered Europe Key Topics Covered: Executive SummaryScope and Definition1 Market: Industry Outlook1.1 Trends: Current and Future Impact Assessment1.1.1 Adoption of Digital Twins in Battery Testing1.1.2 Wireless and Automated Testing Systems1.1.3 AI and Machine Learning in Battery Testing1.1.4 Blockchain for Transparent Certification and Testing1.1.5 Automation and Robotics in Battery Inspection1.1.6 Advanced Material Testing for Next-Gen EV Batteries1.1.7 Innovations in Simulation and Predictive Analytics for Battery Certification1.1.8 Testing of Second-Life Batteries and Recycling Applications1.2 Supply Chain Overview1.2.1 Key Stakeholders1.2.1.1 Raw Material Testing1.2.1.2 Battery Manufacturing and Integration1.2.1.3 Testing and Certification Service Providers1.2.1.4 End-Use Industries1.2.2 Value Chain Analysis1.2.3 Pricing Forecast1.3 Research and Development Review1.3.1 Patent Filing Trend (by Country and Company)1.4 Regulatory Landscape1.5 Services Overview1.5.1 Testing1.5.1.1 Performance Testing1.5.1.2 Durability Testing1.5.1.3 Electrical Testing1.5.1.4 Thermal Testing1.5.1.5 Abuse and Crash Testing1.5.1.6 Non-Destructive Testing (NDT)1.5.2 Inspection1.5.2.1 Visual Inspection1.5.2.2 Safety Inspection1.5.2.3 Quality Control Inspection1.5.3 Certification1.5.3.1 Product Certification (ISO, IEC)1.5.3.2 Safety and Compliance Certification1.5.3.3 Environmental Certification (RoHS, WEEE)1.5.3.4 Regulatory Certification1.6 Impact of COVID-19 on the Industry1.7 Market Dynamics Overview1.7.1 Market Drivers1.7.1.1 Rising Electric Car Sales Accelerating Demand for Reliable and Certified Batteries1.7.1.2 Growing Emphasis on Safety Standards for EV Batteries1.7.2 Market Challenges1.7.2.1 High Costs of Advanced EV Battery Testing Equipment and Facilities1.7.2.2 Lack of Standardized Testing and Certification Requirements for EV Batteries across Markets1.7.3 Market Opportunities1.7.3.1 Increasing Development of Next-Generation EV Batteries1.7.3.2 Expanding Market for Second-Life Applications and Recycling of EV Batteries2 Regions2.1 Regional Summary2.2 Europe2.2.1 Regional Overview2.2.2 Driving Factors for Market Growth2.2.3 Factors Challenging the Market2.2.3.1 Application2.2.3.2 Product2.2.4 Germany2.2.4.1 Application2.2.4.2 Product2.2.5 France2.2.5.1 Application2.2.5.2 Product2.2.6 U.K.2.2.6.1 Application2.2.6.2 Product2.2.7 Spain2.2.7.1 Application2.2.7.2 Product2.2.8 Sweden2.2.8.1 Application2.2.8.2 Product2.2.9 Poland2.2.9.1 Application2.2.9.2 Product2.2.10 Rest-of-Europe2.2.10.1 Application2.2.10.2 Product3 Markets - Competitive Landscaped and Companies Profiled3.1 Next Frontiers3.2 Geographical Assessment3.3 Competitive Landscape3.4 Company Profiles3.4.1 Overview3.4.2 Top Products/Product Portfolio3.4.3 Top Competitors3.4.4 Target Customers/End-Use Industries3.4.5 Key Personnel3.4.6 Analyst View3.4.7 Market Share, 20234 Research Methodology4.1 Data Sources4.1.1 Primary Data Sources4.1.2 Secondary Data Sources4.1.3 Data Triangulation4.2 Market Estimation and Forecast For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment European Electric Vehicle Battery Testing, Inspection, and Certification Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Hamilton Spectator

2 hours ago

• Hamilton Spectator

Prime Minister Carney in Brussels today for EU-Canada summit

BRUSSELS - Prime Minister Mark Carney is in Belgium today, where he visited a military cemetery before meeting with European Union leaders at an EU-Canada summit. Carney said on social media Sunday that he was in Brussels to launch 'a new era of partnership' between Canada and the European Union for the benefit of workers, businesses and security 'on both sides of the Atlantic.' Carney started the day with a visit to the Antwerp Schoonselhof Military Cemetery where 348 Canadian soldiers are buried. Later, he is expected to meet with Belgian Prime Minister Bart De Wever, European Council President António Costa and European Commission President Ursula von der Leyen. Carney posted on social media early on Monday that he spoke with U.S. President Donald Trump overnight, noting the conversation addressed the need to de-escalate the conflict in the Middle East, their shared commitment of a stronger NATO and progress in ongoing trade talks between Canada and the United States. At the EU-Canada summit, Foreign Affairs Minister Anita Anand and Defence Minister David McGuinty are expected to sign a security and defence agreement with the European bloc in what one European official described last week as one of the most ambitious deals the continent's powers have ever signed with a third country. The security and defence agreement aims to open the door to Canada's participation in the joint purchase of weapons with European countries. It will also lead to Canada's participation in the ReArm Europe initiative, allowing Canada to access a 150-billion-euro program for defence procurement, called Security Action for Europe. Canada will need to sign a second agreement with the European Commission before it can take part in the program. A government official briefing reporters on the trip said the partnership is expected to make procurement easier and more affordable, while also allowing Canada to diversify the sources of equipment. At the EU-Canada summit, leaders are also expected to issue a joint statement to underscore a willingness for continued pressure on Russia to end its war on Ukraine, including through further sanctions, and call for an immediate and permanent ceasefire in Gaza. The joint statement is also expected to touch on climate change, trade and digital and tech policy. Leaders at the EU-Canada summit are also slated to discuss global trade and commit to working towards full ratification and implementation of the Comprehensive Economic and Trade Agreement, the Canada-Europe free trade deal known as CETA. The pact took effect provisionally in 2017, and most of its contents now apply. But all EU countries need to approve CETA before it can take full effect, with 10 members still left to ratify the deal. Carney, Costa and von der Leyen are scheduled to hold a joint press conference in the evening. On Tuesday, Carney travels to The Hague for the NATO summit. The international meetings come as Canada looks to reduce its defence procurement reliance on the United States due to strained relations over tariffs and U.S. President Donald Trump's repeated talk about Canada becoming a U.S. state. This report by The Canadian Press was first published June 23, 2025.